Video

Urology Times 50 Innovations Series: Sacral neuromodulation

Author(s):

Urology Times staff

"[Sacral neuromodulation has] changed the treatment of OAB remarkably," says Howard B. Goldman, MD, FACS.

Urology Times® is celebrating its 50th anniversary in 2022. To mark the occasion, we are highlighting 50 of the top innovations and developments that have transformed the field of urology over the past 50 years. In this installment, Howard Goldman, MD, discusses the development of sacral neuromodulation as a treatment for overactive bladder (OAB). Goldman is a professor of urology and vice chair of the Glickman Urologic Institute at Cleveland Clinic.

Related Videos
Andrew C. Peterson, MD, MPH, answers a question during a Zoom video interview
Raevti Bole, MD, answers a question during a video interview
Illustration of Benign Prostatic Hyperplasia | Image Credit: © Judith - stock.adobe.com
Petar Bajic, MD, answers a question during a video interview
Raevti Bole, MD, answers a question during a video interview
Related Content
iTNM may provide comparable safety, efficacy to SNM for OAB, UUI
November 4th 2024

iTNM may provide comparable safety, efficacy to SNM for OAB, UUI

Hannah Clarke
The UUI responder rate was 71.8% among those who received SNM and 71.3% among those who received iTNM.
Dr. Schwen on focal therapies for prostate cancer
January 11th 2024

Dr. Schwen on focal therapies for prostate cancer

Cleveland Clinic
Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.
Comparable efficacy seen with single vs. multiple OnabotulinumtoxinA injection sites in OAB
October 24th 2024

Comparable efficacy seen with single vs. multiple OnabotulinumtoxinA injection sites in OAB

Hannah Clarke
At 1 month, the mean decrease in the OAB-Q symptom severity subscale score was -31.2 in the 1-injection cohort vs -39.5 in the 10-injection cohort.
Dr. Dobberfuhl discusses novel onabotulinumtoxinA treatment for refractory OAB
March 21st 2022

Dr. Dobberfuhl discusses novel onabotulinumtoxinA treatment for refractory OAB

Urology Times staff
“This technique is feasible, it is very well tolerated, and there’s not much of a complication rate, so it appears to be very safe,” says Amy D. Dobberfuhl, MD, MS.
Pelvic floor yoga is not superior to general physical conditioning for urinary incontinence
August 28th 2024

Pelvic floor yoga is not superior to general physical conditioning for urinary incontinence

Hannah Clarke
Over 12 weeks, the average reduction in total UI frequency was 2.3 episodes per day among those in the pelvic yoga program compared with 1.9 episodes per day among those in the general physical conditioning program.
New telehealth service provides access to Leva System for urinary incontinence
August 13th 2024

New telehealth service provides access to Leva System for urinary incontinence

Hannah Clarke
Data from a real-world evidence study of the Leva System were recently published in JMIR Formative Research, supporting the safety and effectiveness of the program in the treatment of patients with urinary incontinence.
© 2024 MJH Life Sciences

All rights reserved.